Webcast / Audiocast

0 Comments

31 March 2017

Pioneer AF

Dr Dwayne Conway

Pinderfields Hospital
Yorkshire

Previous | Next

Summary

Dr Conway presents the PIONEER-AF trial, which assesses optimal antithrombotic therapy when both dual anti-platelet therapy and anticoagulant therapy is required.

Patient who underwent recent PCI and atrial fibrillation were included (excluding those with recent bleeds e.g. haemorrhagic stroke or those with stent thromboses or staged PCI).

Patients were randomised into three groups: warfarin + DAPT (mostly clopidogrel), rivaroxaban + single antiplately agent (no aspirin) or rivaroxaban + aspirin.

 

Summary

Dr Conway presents the PIONEER-AF trial, which assesses optimal antithrombotic therapy when both dual anti-platelet therapy and anticoagulant therapy is required.

Patient who underwent recent PCI and atrial fibrillation were included (excluding those with recent bleeds e.g. haemorrhagic stroke or those with stent thromboses or staged PCI).

Patients were randomised into three groups: warfarin + DAPT (mostly clopidogrel), rivaroxaban + single antiplately agent (no aspirin) or rivaroxaban + aspirin.

 

You have to be a BCIS member to access this content

Either Sign in or register to become a member, today! Join BCIS Sign In